• Crowdfunding industry-History, development, policies, and potential issues

      Zhao, Ying; Harris, Phil; Lam, Wing (Wiley, 2019-03-14)
    • Crowdfunding industry-History, development, policies, and potential issues

      Zhao, Ying; Harris, Phil; Lam, Wing (Wiley, 2019-03-14)
    • One strategy does not fit all: determinants of urban adaptation in mammals

      Santini, Luca; González-Suárez, Manuela; Russo, Danilo; Gonzalez-Voyer, Alejandro; von Hardenberg, Achaz; Ancillotto, Leonardo (Wiley, 2018-12-20)
    • Perspectives on New Gambia

      Perfect, David (Informa UK Limited, 2019-02-05)
    • Alzheimer's Amyloidopathy: An Alternative Aspect.

      Regland, Björn; McCaddon, Andrew (2019-02-20)
      The 'amyloid hypothesis' dominates Alzheimer's disease (AD) research but has failed to deliver effective therapies. Amyloid precursor protein (APP) and presenilin-1 (PSEN1) genetic mutations are undoubtedly pathogenic, albeit by unclear mechanisms. Conversely, high dose B-vitamins convincingly slow brain atrophy in a pre-stage state of sporadic AD. Here we suggest a link between sporadic and genetic AD: 1) Increased serum homocysteine, a marker of B-vitamin deficiencies, is a significant risk factor for sporadic AD. It also correlates with elevated levels of antichymotrypsin, a serine protease inhibitor. 2) Family members with codon 717 APP mutations and dementia have low serum vitamin B12 values. Overexpression of the APP domain coding for a Kunitz type serine protease inhibitor might explain this. 3) PSEN1 mutations disrupt lysosomal function due to reduced proteolytic activity. They also trap cobalamin (B12) within lysosomes, leading to intracellular deficiency of the vitamin. In summary, APP and PSEN1 mutations both confer a risk for reduced protease activity and B12 bio-availability. Comparably, sporadic AD features a constellation of increased protease inhibition and B-vitamin deficiencies, the central part of which is believed to be B12. These concordant observations in three disparate AD etiologies suggest a common neuropathogenic pathway. This hypothesis is evaluable in laboratory and clinical trials.
    • Chemical Plants: Performance Measurement of Processes

      Moran, Sean; Dhafr, Nasreddin; Ahmad, Munir (Wiley-VCH Verlag GmbH & Co. KGaA, 2017-03-30)
    • Emerging technologies for food and drug safety.

      Slikker, William; email: william.slikker@fda.hhs.gov; de Souza Lima, Thalita Antony; Archella, Davide; de Silva, Jarbas Barbosa; Barton-Maclaren, Tara; Bo, Li; Buvinich, Danitza; Chaudhry, Qasim; Chuan, Peiying; Deluyker, Hubert; Domselaar, Gary; Freitas, Meiruze; Hardy, Barry; Eichler, Hans-Georg; Hugas, Marta; Lee, Kenneth; Liao, Chia-Ding; Loo, Lit-Hsin; Okuda, Haruhiro; Orisakwe, Orish Ebere; Patri, Anil; Sactitono, Carl; Shi, Leming; Silva, Primal; Sistare, Frank; Thakkar, Shraddha; Tong, Weida; Valdez, Mary Lou; Whelan, Maurice; Zhao-Wong, Anna (2018-07-23)
      Emerging technologies are playing a major role in the generation of new approaches to assess the safety of both foods and drugs. However, the integration of emerging technologies in the regulatory decision-making process requires rigorous assessment and consensus amongst international partners and research communities. To that end, the Global Coalition for Regulatory Science Research (GCRSR) in partnership with the Brazilian Health Surveillance Agency (ANVISA) hosted the seventh Global Summit on Regulatory Science (GSRS17) in Brasilia, Brazil on September 18-20, 2017 to discuss the role of new approaches in regulatory science with a specific emphasis on applications in food and medical product safety. The global regulatory landscape concerning the application of new technologies was assessed in several countries worldwide. Challenges and issues were discussed in the context of developing an international consensus for objective criteria in the development, application and review of emerging technologies. The need for advanced approaches to allow for faster, less expensive and more predictive methodologies was elaborated. In addition, the strengths and weaknesses of each new approach was discussed. And finally, the need for standards and reproducible approaches was reviewed to enhance the application of the emerging technologies to improve food and drug safety. The overarching goal of GSRS17 was to provide a venue where regulators and researchers meet to develop collaborations addressing the most pressing scientific challenges and facilitate the adoption of novel technical innovations to advance the field of regulatory science. [Abstract copyright: Published by Elsevier Inc.]